Blog
RSS FeedPosted by Michael Wonder on 24 Aug 2021
Method paper: IQWiG puts draft version 6.1 up for discussion
23 August 2021 - The IQWiG has presented the draft for the next version of its General Methods. ...
Posted by Michael Wonder on 16 Aug 2021
Spinal muscular atrophy: second and third active ingredients undergo benefit assessment
16 August 2021 - With risdiplam there is a hint of an added benefit for spinal muscular atrophy type 1, ...
Posted by Michael Wonder on 16 Aug 2021
Lanadelumab in hereditary angioedema: added benefit not proven
16 August 2021 - The active ingredient has exceeded the sales limit for the simplified orphan drug assessment. There are no ...
Posted by Michael Wonder on 15 Jul 2021
G-BA sees “considerable additional benefit” in two active ingredients - EU HTA analysis is coming
15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns ...
Posted by Michael Wonder on 05 Jul 2021
Remdesivir in COVID-19: indication of considerable added benefit for a part of the patients
1 July 2021 - COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover ...
Posted by Michael Wonder on 16 Jun 2021
German law makers seek to ease reimbursement for advanced therapies
15 June 2021 - Advanced therapy trade group The Alliance for Regenerative Medicine has highlighted the passage of a new ...
Posted by Michael Wonder on 31 May 2021
New EU health innovation rules edge closer
29 May 2021 - Three years after the original proposal, the European Union’s game changing Health Technology Assessment dossier has ...
Posted by Michael Wonder on 29 Apr 2021
Developing a quality management system for the European Network for Health Technology Assessment (EUnetHTA): toward European HTA collaboration
27 April 2021 - The European Network for Health Technology Assessment (EUnetHTA) was established in 2006 and comprises over eighty organisations ...
Posted by Michael Wonder on 22 Apr 2021
Novartis to discontinue sales of Piqray in Germany
21 April 2021 - The sale of Piqray (alpelisib) will be discontinued by Novartis in accordance with Section 4 (7) ...
Posted by Michael Wonder on 22 Mar 2021
Early benefit assessment - the whole spectrum
19 March 2021 - IQWiG evaluated a total of 24 manufacturer dossiers punctually for the dates March 1 and March 15. ...
Posted by Michael Wonder on 01 Mar 2021
Dapagliflozin in chronic heart failure: hint of added benefit
1 March 2021 - Diabetes drug is also effective in symptomatic chronic heart failure with reduced pump function. However, the additional ...
Posted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...
Posted by Michael Wonder on 03 Dec 2020
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment
3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...
Posted by Michael Wonder on 02 Dec 2020
IQWiG publishes 1,000th report
2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...
Posted by Michael Wonder on 19 Nov 2020
Trifarotene in moderate acne: no study data for the assessment of the added benefit
16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...